ISSN 0513-4870 CN 11-2163/R

药学学报

第54卷 第6期
2019 Vol. 54 No. 6



Acta Pharmaceutica Sinica

专家论坛

余露山, 曾 苏等
2018年中国药物代谢研究进展

研究论文

周丹丹, 花 芳等
TRIM25增强EGFR稳定性及信号促进肺癌发展

中国药学会
中国医学科学院药物研究所

药 学 学 报

第 54 卷　第 6 期　2019 年 6 月

图 文 摘 要

专家论坛

963

2018 年中国药物代谢研究进展

余露山[1]，毕惠嫦[2]，吴宝剑[3]，葛广波[4]，郑江[5,6]，乔海灵[7]，曾苏[1*]

(1. 浙江大学药学院，浙江 杭州 310058；2. 中山大学药学院，广东 广州 510006；3. 暨南大学药学院，广东 广州 510632；4. 上海中医药大学交叉科学研究院，上海 201203；5. 沈阳药科大学，辽宁 沈阳 110016；6. 贵州医科大学，贵州 贵阳 550004；7. 郑州大学基础医学院，河南 郑州 450001)

该文总结了 2018 年中国学者在 DMPK 领域取得的重要研究成果并展望了该领域未来的研究热点。

综述

971

JAK2 抑制剂治疗骨髓增殖性肿瘤研究进展

胡敏，史高娜，石建功*，张天泰*

(中国医学科学院，北京协和医学院药物研究所，北京 100050)

本文介绍了 JAK2 作为 MPNs 的治疗靶点，JAK2 激酶的功能特点与该疾病的关系以及 JAK2 小分子抑制剂的研发现状。



978

磷酸甘油酸激酶 1 与肿瘤

王玉英[1]，戚欣[1]，李静[1,2*]

(1. 中国海洋大学医药学院，海洋药物教育部重点实验室，山东 青岛 266003；2. 青岛海洋科学与技术国家实验室-海洋药物与生物制品实验室，山东 青岛 266237)

磷酸甘油酸激酶 1 (PGK1) 糖酵解过程中关键的催化酶，对肿瘤细胞能量和物质的供给至关重要。而且 PGK1 作为一种癌蛋白在多种肿瘤细胞中高表达，促进肿瘤的发生发展，还与肿瘤患者的不良预后有关，是肿瘤治疗的潜在靶点。



984

药物调节自噬治疗阿尔茨海默病

谭成勇[1]，田慧珍[1]，况煌[1]，洪芬芳[2*]，杨树龙[1*]

(1. 南昌大学基础医学院，江西 南昌 330031；2. 南昌大学基础医学实验教学中心，江西 南昌 330006)

一些植物提取化合物和其他药物，通过各种通路调节自噬，进而调节可影响体内 Aβ 和 Tau 水平的自噬底物水平，是缓解或治疗阿尔兹海默病有前景的药物。











研究论文





















新药发现与研究实例简析

信息

ACTA PHARMACEUTICA SINICA

Volume 54 Number 6 2019 June

Graphical Abstracts

Professionals Forum

963

2018 DMPK research progress in China

YU Lu-shan[1], BI Hui-chang[2], WU Bao-jian[3], GE Guang-bo[4], ZHENG Jiang[5,6], QIAO Hai-ling[7], ZENG Su[1*]

(1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China; 2. School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China; 3. School of Pharmacy, Jinan University, Guangzhou 510632, China; 4. Institute of Interdisciplinary Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China; 5. Shenyang Pharmaceutical University, Shenyang 110016, China; 6. School of Pharmacy, Guizhou Medical University, Guiyang 550004, China; 7. Basic Medical College, Zhengzhou University, Zhengzhou 450001, China)



This paper summarizes the important research achievements in the field of DMPK by Chinese scholars in 2018 and looks forward to the future research hotspots in this field.

Reviews

971

Advances in JAK2 inhibitors for treatment of myeloproliferative neoplasms

HU Min, SHI Gao-na, SHI Jian-gong*, ZHANG Tian-tai*

(Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China)



This review describes the targets of JAK2 in MPNs, the latest progress of the relationship between JAK2 and MPNs, JAK2 inhibitors for the treatment of MPNs.

978

Phosphoglycerate kinase 1 and cancer

WANG Yu-ying[1], QI Xin[1], LI Jing[1,2*]

(1. Key Laboratory of Marine Drugs, Chinese Ministry of Education, School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China; 2. Laboratory for Marine Drugs and Bioproducts of Qingdao National Laboratory for Marine Science and Technology, Qingdao 266237, China)



Phosphoglycerate kinase 1 (PGK1) is a key metabolic enzyme in the glycolysis pathway, which is essential for the supply of energy and substrates to cancer cells. Besides, as an oncogenic protein, PGK1 expression is upregulated in many types of human cancer, which promotes the development and progression of tumors and correlates poor survival of cancer patients.

Original Articles

ACTA PHARMACEUTICA SINICA

Volume 54 Number 6 2019 June

期刊基本参数: CN 11-2163/R*1953*m*A4*182*zh*P* ￥40.00* *24*2019-06

本期责任编辑 岳 瑞

药学学报 (YAOXUE XUEBAO)

(月刊, 1953 年 7 月创刊)

主管单位: 中国科学技术协会

主办单位: 中国药学会 (http://www.cpa.org.cn)
中国医学科学院药物研究所
(http://www.imm.ac.cn)

编辑出版: 药学学报编辑部 (100050 北京市先农坛街 1 号)
电话/传真: 86-10-63026192, 63035012;
电子信箱: yxxb@imm.ac.cn;
网址: http://www.yxxb.com.cn

主编: 王晓良

印刷: 北京科信印刷有限公司

国内订购: 全国各地邮电局

发行范围: 公开发行

国 内: 北京报刊发行局

国 外: 中国国际图书贸易集团有限公司
(北京市 399 信箱, 100044)

ACTA PHARMACEUTICA SINICA

(Monthly, Founded in 1953 July)

Directed by: China Association for Science and Technology

Sponsored by: Chinese Pharmaceutical Association
(http://www.cpa.org.cn)
Institute of Materia Medica, Chinese Academy of Medical Sciences (http://www.imm.ac.cn)

Edited and Published by: Editorial Office of Acta Pharmaceutica Sinica
(1 Xiannongtan Street, Beijing 100050).
Tel / Fax: 86-10-63026192, 63035012;
E-mail: yxxb@imm.ac.cn; http://www.yxxb.com.cn

Editor-in-chief: WANG Xiao-liang

Printed by: Beijing Kexin Printing Co., Ltd.

Domestic subscriptions: Local Post Offices

Distribution

Domestic: Beijing Post Offices

Foreign: China International Book Trading Corporation,
PO Box 399, Beijing 100044, China

ISSN 0513-4870
CN 11-2163/R

2019 年 第 54 卷 第 6 期
2019, Vol. 54, No.6

2019 年 6 月 12 日出版
Publication Date: 2019-06-12

邮发代号: 2-233
Code number: M105
国内定价: 每期 40.00 元

ISSN 0513-4870